文献速递白血病淋巴瘤

RNA解旋酶DDX19A/B通过调控MCL1 mRNA核输出调节白血病细胞对塞利尼索的敏感性

The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells.
PubMed 文献 · Leukemia · 2024-07-11

研究利用全基因组CRISPR/Cas9敲除筛选在两种B-ALL细胞系中鉴定调控塞利尼索敏感性的关键分子,首次发现旁系同源RNA解旋酶DDX19A和DDX19B通过调控MCL1 mRNA核输出影响MCL1蛋白水平。同时敲低DDX19A和DDX19B显著减弱MCL1 mRNA核输出并降低MCL1蛋白,塞利尼索联合敲低任一DDX19基因可显著诱导白血病细胞内在凋亡,该效应可被MCL1过表达挽救。Depmap数据分析显示部分T-ALL细胞系DDX19B mRNA表达极低,塞利尼索处理或DDX19A敲低可有效诱导这些低表达DDX19B的T-ALL细胞系凋亡。作者认为DDX19A/B可作为塞利尼索治疗的生物标志物,药理学靶向DDX19旁系同源物可能是诱导白血病细胞内在凋亡的潜在策略。

要点

  • 全基因组CRISPR/Cas9敲除筛选鉴定DDX19A/B调控塞利尼索敏感性。
  • 同时敲低DDX19A和DDX19B减弱MCL1 mRNA核输出并降低MCL1蛋白。
  • 塞利尼索联合敲低DDX19A或DDX19B诱导凋亡,可被MCL1过表达挽救。

核心结论

  • XPO1与DDX19A/B协同调控细胞MCL1水平,DDX19A/B可作为塞利尼索治疗的生物标志物。
  • 药理学靶向DDX19旁系同源物可能是诱导白血病细胞内在凋亡的潜在策略。

研究设计与样本

  • 研究利用两种B-ALL细胞系进行全基因组CRISPR/Cas9敲除筛选以鉴定调控塞利尼索敏感性的关键分子/通路。
  • 研究分析Depmap数据集评估T-ALL细胞系DDX19B mRNA表达水平。

主要发现

  • 单独敲低DDX19A或DDX19B几乎不改变MCL1蛋白水平,同时敲低两者显著减弱MCL1 mRNA核输出并降低MCL1蛋白水平。
  • 塞利尼索处理联合敲低DDX19A或DDX19B显著诱导白血病细胞内在凋亡,该效应可被MCL1过表达挽救。
  • Depmap数据集分析显示一部分T-ALL细胞系表达极低水平的DDX19B mRNA。
  • 塞利尼索处理或DDX19A敲低均有效诱导表达低DDX19B水平的T-ALL细胞系凋亡。

临床怎么用

  • 作者提出DDX19A/B可作为塞利尼索治疗的生物标志物。
  • 作者认为药理学靶向DDX19旁系同源物可能是诱导白血病细胞内在凋亡的潜在策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selinexor, a first-in-class exportin1 (XPO1) inhibitor, is an attractive anti-tumor agent because of its unique mechanisms of action; however, its dose-dependent toxicity and lack of biomarkers preclude its wide use in clinical applications. To identify key molecules/pathways regulating selinexor sensitivity, we performed genome-wide CRISPR/Cas9 dropout screens using two B-ALL lines. We identified, for the first time, that paralogous DDX19A and DDX19B RNA helicases modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export. While single depletion of either DDX19A or DDX19B barely altered MCL1 protein levels, depletion of both significantly attenuated MCL1 mRNA nuclear export, reducing MCL1 protein levels. Importantly, combining selinexor treatment with depletion of either DDX19A or DDX19B markedly induced intrinsic apoptosis of leukemia cells, an effect rescued by MCL1 overexpression. Analysis of Depmap datasets indicated that a subset of T-ALL lines expresses minimal DDX19B mRNA levels. Moreover, we found that either selinexor treatment or DDX19A depletion effectively induced apoptosis of T-ALL lines expressing low DDX19B levels. We conclude that XPO1 and DDX19A/B coordinately regulate cellular MCL1 levels and propose that DDX19A/B could serve as biomarkers for selinexor treatment. Moreover, pharmacological targeting of DDX19 paralogs may represent a potential strategy to induce intrinsic apoptosis in leukemia cells.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Terasaki T, Semba Y, Sasaki K, et al. The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells. Leukemia. 2024. PMID: 38987275. doi:10.1038/s41375-024-02343-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。